Navigation Links
Instanyl sets new standard in management of breakthrough cancer pain
Date:9/11/2009

Lisbon, Portugal 11 September, 2009 New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer. The study concludes that pain relief was significantly greater for Instanyl compared to OTFC at all time points:

  • 25% of episodes showed meaningful pain relief already at 5 minutes after treatment with Instanyl, as compared to 7% with OTFC. (p<0.001) (1)

  • 51% of the Instanyl treated patients had a meaningful pain relief at 10 minutes, as compared to 24% with OTFC. (p<0.001) (1)

"These data confirm the superiority of the intranasal drug administration over OTFC. Rapid pain relief is essential for the management of breakthrough cancer pain and with evidence of onset of pain relief as early as 5 minutes, Instanyl offers patients a much more effective pain control than OTFC," said Professor Sebastiano Mercadante, principal investigator of the comparative study and Director of the Anesthesia and Intensive Care and Pain Relief and Palliative Care Units at La Maddalena Cancer Center, Palermo, Italy.

The study also showed that patients found Instanyl significantly easier to administer than OTFC, with 90% of patients finding Instanyl 'easy' or 'very easy' to use, compared to 40% of OTFC patients (2). Instanyl is the first intranasal treatment for breakthrough cancer pain to be licensed and the study showed that 77% of patients preferred Instanyl to OTFC (2).

"With a preference for Instanyl more than three-fold higher compared to OTFC the study confirms that with Instanyl patients now have a treatment that they feel better matches their need," said Professor Mercadante and concluded: "Instanyl represents a major step forward in the management of breakthrough cancer pain."

Up to 95% of patients with cancer pain experience breakthrough pain (3) of which two-thirds experience inadequate pain control (4). Interim results from the first European survey of breakthrough cancer pain (5) also presented for the first time in Lisbon show that on average a patient will have 3 episodes of BTCP per day, each one lasting on average 60 minutes and 96% of episodes being rated as moderate or severe. 87% of patients reported that their BTCP interfered with their daily living including their ability to sleep, walk and get on with other people.

"Breakthrough cancer pain afflicts a large proportion of cancer patients yet there is a significant under-treatment and sub-optimal treatment of these patients. Time has come for a change in management of breakthrough cancer pain and with Instanyl now approved we have an intranasal product with fast onset of pain relief, short duration which is easy to use. This will enable us to improve the care of cancer patients," commented President of EFIC, Professor Giustino Varrassi, Dept. of Anesthesiology and Pain Medicine L'Aquila University, Italy.

Instanyl is approved for the management of breakthrough cancer pain in adults already receiving maintenance opioid therapy for chronic cancer pain. This first-in class drug was granted marketing authorisation on the 20th July 2009, and will be launched across Europe from September 2009.


'/>"/>

Contact: Mette Thorn Srensen
mts@cohnwolfe.dk
454-138-4300
Cohn & Wolfe, Copenhagen
Source:Eurekalert

Related medicine news :

1. Newly Published Clinical Study Finds New Commercial Diet Program Superior to Standard Protocol for Diabetes Weight Loss and Blood Sugar Control
2. GHX Working with Hospitals and Suppliers to Enable Use of Industry Standard Location and Organization Identifiers in Transactions and Compliance with GLN Sunrise Date
3. Quality of Medicines Advanced by Agreement Between USP, Mexican Standards Body
4. Standard & Poor's Upgrades Wellmont Outlook
5. New Study Reveals VASER(R) Lipo to be the New Standard of Care for Body Contouring and Fat Transfer Procedures
6. Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device
7. NMB's New Series of Standard Hybrid Stepper Motors Now Available
8. Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards
9. CAS REGISTRY(SM), the Global Standard for Chemical Research, Approaches 50 Millionth Registration Milestone
10. Sedationfacts.org Enhances State-Specific Site Content, Making Regional Sedation Administration Standards and Regulations Quick and Easy to Find and Use
11. Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Bensonhurst, NY (PRWEB) , ... May 23, 2016 , ... ... Enrico Ferdico took the time to summarize the weight loss process: , New patients ... a Body Composition Analysis (BCA) to get accurately evaluated. , Body Composition Analysis, There ...
(Date:5/23/2016)... , ... May 23, 2016 , ... According to an article published May ... massive role in oral health and hygiene. The article points out that, as long as ... their toothbrushes will become worn and frayed. Of course, these worn-out bristles won’t clean teeth ...
(Date:5/23/2016)... , ... May 23, 2016 , ... According to an ... in an exuberant mood since the birth of her son, Rockwell Lloyd Liu, and ... ever had.” The “Elementary” and “Kill Bill” star explains that, as a career oriented ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Clinical Data ... from the Japan PMDA, US FDA, industry and academia at the 2016 ... format data from clinical trials so that it can be shared and compared, ...
(Date:5/23/2016)... ... ... NYDNRehab, a New York City-based physical therapy clinic , is introducing ... type of technology, which was developed by world-renowned researcher Dr. Christopher Powers of University ... With over 10 million sport injuries per year in the United States, ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... According to a new market research report "Sunitinib Malate ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected to ... from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... through 26 Pages and in-depth TOC on "Sunitinib Malate ...
(Date:5/19/2016)... , May 19, 2016 , The ... (a bstract # 8006)   The ... of the treated patients with 90% of the ... six months or more . Seventy two percent of the patients had ... (MSE:PHM) announces the positive results from a Phase I study of plitidepsin in ...
(Date:5/19/2016)... NEW YORK , May 19, 2016 ... one sector that is always abounding of surprises is without ... the Healthcare sector ahead of today,s trading session: Alkermes PLC ... AMAG ), IDEXX Laboratories Inc. (NASDAQ: IDXX ... Sign up for your complimentary alerts at: ...
Breaking Medicine Technology: